What is Vidara?
Darunavir, cobicistat, emtricitabine, and Vidara alafenamide combination is used to treat human immunodeficiency virus (HIV) infection. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). Darunavir, cobicistat, emtricitabine, and Vidara alafenamide is usually given to patients who have yet not received any medicine for HIV infection.
Darunavir, cobicistat, emtricitabine, and Vidara alafenamide combination will not cure or prevent HIV infection or AIDS. It helps keep HIV from reproducing and appears to slow down the destruction of the immune system. This may help delay problems that are usually related to AIDS or HIV disease from occurring. Darunavir, cobicistat, emtricitabine, and Vidara alafenamide will not keep you from spreading HIV to other people. People who receive darunavir, cobicistat, emtricitabine, and Vidara alafenamide may continue to have other problems usually related to AIDS or HIV disease.
Darunavir, cobicistat, emtricitabine, and Vidara alafenamide is available only with your doctor's prescription.
HIV-1 Infection: Vidara is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.
The following points should be considered when initiating therapy with Vidara for the treatment of HIV-1 infection: Vidara should not be used in combination with STRIBILD, TRUVADA or other products containing Vidara disoproxil fumarate.
Chronic Hepatitis B: Vidara is indicated for the treatment of chronic hepatitis B in adults. The following points should be considered when initiating therapy with Vidara for the treatment of HBV infection: The indication in adults is based on safety and efficacy data from treatment of subjects who were nucleoside-treatment-naïve and subjects who were treatment-experienced with documented resistance to lamivudine. Subjects were adults with HBeAg-positive and HBeAg-negative chronic hepatitis B with compensated liver disease.
Vidara was evaluated in a limited number of subjects with chronic hepatitis B and decompensated liver disease..
The numbers of subjects in clinical trials who had adefovir resistance-associated substitutions at baseline were too small to reach conclusions of efficacy.
Vidara is indicated for the treatment of chronic hepatitis B in adolescents 12 to <18 years of age with: Compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis.
How should I use Vidara?
Use Vidara powder as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Vidara powder. Talk to your pharmacist if you have questions about this information.
- Take Vidara powder by mouth with food as directed.
- Only use the dosing scoop that comes with Vidara powder to measure your dose. Ask your pharmacist for help if you are unsure of how to measure your dose.
- Wash and dry your hands immediately before preparing your dose.
- Mix the prescribed dose of Vidara powder with 1/4 to 1/2 cup (2 to 4 oz) of a soft food that can be swallowed without chewing (eg, applesauce, baby food, yogurt). Do NOT mix Vidara powder with liquid. It may float to the top even after stirring.
- Stir the mixture with a spoon until it is well mixed. Take your dose right away after mixing to avoid a bad taste.
- Wash and dry the dosing scoop after each use. Do NOT store it in the bottle.
- Continue to take Vidara powder even if you feel well. Do not miss any doses.
- Taking Vidara powder at the same time each day will help you remember to take it.
- Do not suddenly stop taking Vidara powder without checking with your doctor. This may cause the virus to become less sensitive to this or other medicines. If you have hepatitis B, your condition could become worse if you suddenly stop taking Vidara powder.
- If you miss a dose of Vidara powder, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Vidara powder.
Uses of Vidara in details
Vidara is used in combination with other antiviral drugs in the treatment of human immunodeficiency virus (HIV) infections. It may also be used in very limited cases of long-term infections of liver caused by hepatitis B virus.
Vidara is the brand name for Vidara disoproxil fumarate (a prodrug of Vidara) which is a fumaric acid salt of bis-isopropoxycarbonyloxymethyl ester derivative of Vidara. In vivo Vidara disoproxil fumarate is converted to Vidara, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. Vidara exhibits activity against HIV-1 reverse transcriptase.
The chemical name of Vidara disoproxil fumarate is 9-[(R)2[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphinyl]methoxy]propyl]adenine fumarate (1:1). It has a molecular formula of C19H30N5O10P·C4H4O4 and a molecular weight of 635.52.
Vidara disoproxil fumarate is a white to off-white crystalline powder with a solubility of 13.4 mg/mL in distilled water at 25°C. It has an octanol/phosphate buffer (pH 6.5) partition coefficient (log p) of 1.25 at 25°C.
Vidara tablets are for oral administration. Each tablet contains 300 mg of Vidara disoproxil fumarate, which is equivalent to 245 mg of Vidara disoproxil.
Excipients/Inactive Ingredients: Croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and pregelatinized starch. The tablets are coated with Opadry II Y–30–10671–A, which contains FD&C blue #2 aluminum lake, hypromellose 2910, lactose monohydrate, titanium dioxide, and triacetin.
In this insert, all dosages are expressed in terms of Vidara disoproxil fumarate except where otherwise noted.
Recommended Dose In Adults And Pediatric Patients 12 Years Of Age And Older (35 kg or more)
For the treatment of HIV-1 or chronic hepatitis B: The dose is one 300 mg Vidara tablet once daily taken orally, without regard to food.
For patients unable to swallow Vidara tablets, the oral powder formulation (7.5 scoops) may be used.
In the treatment of chronic hepatitis B, the optimal duration of treatment is unknown. Safety and efficacy in pediatric patients with chronic hepatitis B weighing less than 35 kg have not been established.
Recommended Dose In Pediatric Patients 2 Years To Less Than 12 Years Of Age
For the treatment of HIV-1 in pediatric patients 2 years of age and older, the recommended oral dose of Vidara is 8 mg of Vidara disoproxil fumarate per kilogram of body weight (up to a maximum of 300 mg) once daily administered as oral powder or tablets.
Vidara oral powder should be measured only with the supplied dosing scoop. One level scoop delivers 1 g of powder which contains 40 mg of Vidara disoproxil fumarate. Vidara oral powder should be mixed in a container with 2 to 4 ounces of soft food not requiring chewing (e.g., applesauce, baby food, yogurt). The entire mixture should be ingested immediately to avoid a bitter taste. Do not administer Vidara oral powder in a liquid as the powder may float on top of the liquid even after stirring. Further patient instructions on how to administer Vidara oral powder with the supplied dosing scoop are provided in the FDA-approved patient labeling (Patient Information).
Vidara is also available as tablets in 150, 200, 250 and 300 mg strengths for pediatric patients who weigh greater than or equal to 17 kg and who are able to reliably swallow intact tablets. The dose is one tablet once daily taken orally, without regard to food.
Tables 1 and 2 contain dosing recommendations for Vidara oral powder and tablets based on body weight. Weight should be monitored periodically and the Vidara dose adjusted accordingly.
Table 1 : Dosing Recommendations for Pediatric Patients ≥ 2 Years of Age Using
|Body Weight Kilogram (kg)|| |
Oral Powder Once Daily
Scoops of Powder
|10 to < 12||2|
|12 to < 14||2.5|
|14 to < 17||3|
|17 to < 19||3.5|
|19 to < 22||4|
|22 to < 24||4.5|
|24 to < 27||5|
|27 to < 29||5.5|
|29 to < 32||6|
|32 to < 34||6.5|
|34 to < 35||7|
Table 2: Dosing Recommendations for Pediatric Patients ≥ 2 Years of Age and Weighing ≥ 17 kg Using Vidara Tablets
|Body Weight Kilogram (kg)||Tablets Once Daily|
|17 to < 22||150 mg|
|22 to < 28||200 mg|
|28 to < 35||250 mg|
|≥ 35||300 mg|
Chronic Hepatitis B
Safety and efficacy of Vidara in patients younger than 12 years of age have not been established.
Dose Adjustment For Renal Impairment In Adults
Significantly increased drug exposures occurred when Vidara was administered to subjects with moderate to severe renal impairment. Therefore, the dosing interval of Vidara tablets 300 mg should be adjusted in patients with baseline creatinine clearance below 50 mL/min using the recommendations in Table 3. These dosing interval recommendations are based on modeling of single-dose pharmacokinetic data in non-HIV and non-HBV infected subjects with varying degrees of renal impairment, including end-stage renal disease requiring hemodialysis. The safety and effectiveness of these dosing interval adjustment recommendations have not been clinically evaluated in patients with moderate or severe renal impairment, therefore clinical response to treatment and renal function should be closely monitored in these patients. There are no data to recommend use of Vidara tablets 150, 200 or 250 mg or Vidara oral powder in patients with renal impairment.
No dose adjustment of Vidara tablets 300 mg is necessary for patients with mild renal impairment (creatinine clearance 50–80 mL/min). Routine monitoring of estimated creatinine clearance, serum phosphorus, urine glucose, and urine protein should be performed in patients with mild renal impairment.
Table 3 : Dosage Adjustment for Patients with Altered Creatinine Clearance
|Creatinine Clearance (mL/min) Generally once weekly assuming three hemodialysis sessions a week of approximately 4 hours duration. Vidara should be administered following completion of dialysis.|
The pharmacokinetics of Vidara have not been evaluated in non-hemodialysis patients with creatinine clearance below 10 mL/min; therefore, no dosing recommendation is available for these patients.
No data are available to make dose recommendations in pediatric patients with renal impairment.
Dosage Forms And Strengths
Vidara is available as tablets or as an oral powder.
Vidara tablets 150 mg contain 150 mg of Vidara disoproxil fumarate, which is equivalent to 123 mg of Vidara disoproxil. The tablets are triangle-shaped, white, film-coated, and debossed with “GSI” on one side and “150” on the other side.
Vidara tablets 200 mg contain 200 mg of Vidara disoproxil fumarate, which is equivalent to 163 mg of Vidara disoproxil. The tablets are round-shaped, white, film-coated, and debossed with “GSI” on one side and “200” on the other side.
Vidara tablets 250 mg contain 250 mg of Vidara disoproxil fumarate, which is equivalent to 204 mg of Vidara disoproxil. The tablets are capsule-shaped, white, film-coated, and debossed with “GSI” on one side and “250” on the other side.
Vidara tablets 300 mg contain 300 mg of Vidara disoproxil fumarate, which is equivalent to 245 mg of Vidara disoproxil. The tablets are almond-shaped, light blue, film-coated, and debossed with “GILEAD” and “4331” on one side and with “300” on the other side.
The oral powder consists of white, taste-masked, coated granules containing 40 mg of Vidara disoproxil fumarate, which is equivalent to 33 mg of Vidara disoproxil, per level scoop. Each level scoop contains 1 gram of oral powder.
Storage And Handling
Vidara tablets, 150 mg, are triangle-shaped, white, film-coated tablets containing 150 mg of Vidara disoproxil fumarate, which is equivalent to 123 mg of Vidara disoproxil, are debossed with “GSI” on one side and with “150” on the other side. Each bottle contains 30 tablets, a desiccant (silica gel canister or sachet), and closed with a child-resistant closure. (NDC 61958-0404-1)
Vidara tablets, 200 mg, are round-shaped, white, film-coated tablets containing 200 mg of Vidara disoproxil fumarate, which is equivalent to 163 mg of Vidara disoproxil, are debossed with “GSI” on one side and with “200” on the other side. Each bottle contains 30 tablets, a desiccant (silica gel canister or sachet), and closed with a child-resistant closure. (NDC 61958-0405-1)
Vidara tablets, 250 mg, are capsule-shaped, white, film-coated tablets containing 250 mg of Vidara disoproxil fumarate, which is equivalent to 204 mg of Vidara disoproxil, are debossed with “GSI” on one side and with “250” on the other side. Each bottle contains 30 tablets, a desiccant (silica gel canister or sachet), and closed with a child-resistant closure. (NDC 61958-0406-1)
Vidara tablets, 300 mg, are almond-shaped, light blue, film-coated tablets containing 300 mg of Vidara disoproxil fumarate, which is equivalent to 245 mg of Vidara disoproxil, are debossed with “GILEAD” and “4331” on one side and with “300” on the other side. Each bottle contains 30 tablets, a desiccant (silica gel canister or sachet), and closed with a child-resistant closure. (NDC 61958-0401-1)
Vidara oral powder consists of white, coated granules containing 40 mg of Vidara disoproxil fumarate, which is equivalent to 33 mg of Vidara disoproxil, per gram of powder and is available in multi-use bottles containing 60 grams of oral powder, closed with a child-resistant closure, and co-packaged with a dosing scoop. (NDC 61958-04031)
Store Vidara tablets and oral powder at 25 °C (77 °F), excursions permitted to 1530 °C (59-86 °F).
Keep the bottle tightly closed. Dispense only in original container. Do not use if seal over bottle opening is broken or missing.
Manufactured for and distributed by: Gilead Sciences, Inc. Foster City, CA 94404. Revised: February 2016
What other drugs will affect Vidara?
This section describes clinically relevant drug interactions with Vidara. Drug interactions trials are described elsewhere in the labeling.
Coadministration of Vidara and didanosine should be undertaken with caution and patients receiving this combination should be monitored closely for didanosineassociated adverse reactions. Didanosine should be discontinued in patients who develop didanosine-associated adverse reactions.
When administered with Vidara, Cmax and AUC of didanosine increased significantly. The mechanism of this interaction is unknown. Higher didanosine concentrations could potentiate didanosine-associated adverse reactions, including pancreatitis and neuropathy. Suppression of CD4cell counts has been observed in patients receiving Vidara with didanosine 400 mg daily.
In patients weighing greater than 60 kg, the didanosine dose should be reduced to 250 mg once daily when it is coadministered with Vidara. In patients weighing less than 60 kg, the didanosine dose should be reduced to 200 mg once daily when it is coadministered with Vidara. When coadministered, Vidara and didanosine EC may be taken under fasted conditions or with a light meal (less than 400 kcal, 20% fat). For additional information on coadministration of Vidara and didanosine, please refer to the full prescribing information for didanosine.
HIV-1 Protease Inhibitors
Vidara decreases the AUC and Cmin of atazanavir. When coadministered with Vidara, it is recommended that atazanavir 300 mg is given with ritonavir 100 mg. Vidara should not be coadministered with atazanavir without ritonavir.
Lopinavir/ritonavir, atazanavir coadministered with ritonavir, and darunavir coadministered with ritonavir have been shown to increase Vidara concentrations. Vidara disoproxil fumarate is a substrate of Pglycoprotein (Pgp) and breast cancer resistance protein (BCRP) transporters. When Vidara disoproxil fumarate is coadministered with an inhibitor of these transporters, an increase in absorption may be observed. Patients receiving Vidara concomitantly with lopinavir/ritonavir, ritonavir-boosted atazanavir, or ritonavir-boosted darunavir should be monitored for Vidara-associated adverse reactions. Vidara should be discontinued in patients who develop Vidara-associated adverse reactions.
Hepatitis C Antiviral Agents
Coadministration of Vidara disoproxil fumarate and HARVONI (ledipasvir/sofosbuvir) has been shown to increase Vidara exposure.
In patients receiving Vidara concomitantly with HARVONI without an HIV-1 protease inhibitor/ritonavir or an HIV-1 protease inhibitor/cobicistat combination, monitor for adverse reactions associated with Vidara disoproxil fumarate.
In patients receiving Vidara concomitantly with HARVONI and an HIV-1 protease inhibitor/ritonavir or an HIV-1 protease inhibitor/cobicistat combination, consider an alternative HCV or antiretroviral therapy, as the safety of increased Vidara concentrations in this setting has not been established. If coadministration is necessary, monitor for adverse reactions associated with Vidara disoproxil fumarate.
Drugs Affecting Renal Function
Since Vidara is primarily eliminated by the kidneys, coadministration of Vidara with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of Vidara and/or increase the concentrations of other renally eliminated drugs. Some examples include, but are not limited to, cidofovir, acyclovir, valacyclovir, ganciclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs.
In the treatment of chronic hepatitis B, Vidara should not be administered in combination with HEPSERA (adefovir dipivoxil).
Vidara side effects
The following adverse reactions are discussed in other sections of the labeling:
- Lactic Acidosis/Severe Hepatomegaly with Steatosis
- Severe Acute Exacerbation of Hepatitis B
- New Onset or Worsening of Renal Impairment
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse Reactions in Adult Subjects with Chronic Hepatitis B and Compensated Liver Disease
The safety assessment of Vidara was based on pooled data through the Week 48 data analysis from 1298 subjects in two randomized, double-blind, active-controlled trials, Study 108 and Study 110, in adult subjects with chronic hepatitis B and compensated liver disease. A total of 866 subjects received Vidara 25 mg once daily.
The proportion of subjects who discontinued treatment with Vidara or Vidara disoproxil fumarate due to adverse reactions of any severity was 1.0% and 1.2%, respectively. Table 1 displays the frequency of the adverse reaction (all Grades) greater than or equal to 5% in the Vidara group.
|Vidara Disoproxil Fumarate |
Renal Laboratory Tests
In a pooled analysis of Studies 108 and 110 in adult subjects with chronic hepatitis B and a median baseline eGFR of 106 and 105 mL per minute (for the Vidara and Vidara disoproxil fumarate [TDF] groups, respectively), mean serum creatinine increased by less than 0.1 mg/dL and median serum phosphorus decreased by 0.1 mg/ dL in both treatment groups. Median change from baseline in eGFR was -1.2 mL per minute in the Vidara group and -5.4 mL per minute in those receiving TDF. The long-term clinical significance of these renal laboratory changes on adverse reaction frequencies between Vidara and TDF is not known.
Decrease in Bone Mineral Density
In a pooled analysis of Studies 108 and 110, the mean percentage change in bone mineral density (BMD) from baseline to Week 48 as assessed by dual-energy X-ray absorptiometry (DXA) was -0.6% with Vidara compared to -2.4% with TDF at the lumbar spine and -0.2% compared to -1.9% at the total hip. BMD declines of 5% or greater at the lumbar spine were experienced by 6% of Vidara subjects and 20% of TDF subjects. BMD declines of 7% or greater at the femoral neck were experienced by 3% of Vidara subjects and 6% of TDF subjects. The long-term clinical significance of these BMD changes is not known.
The frequency of laboratory abnormalities (Grades 3–4) occurring in at least 2% of subjects receiving Vidara in Studies 108 and 110 are presented in Table 2.
|Laboratory Parameter Abnormality*||Vidara |
|Vidara Disoproxil Fumarate |
|ALT (>5 × ULN)||8%||9%|
|LDL-cholesterol (fasted) (>190 mg/dL)||4%||<1%|
|AST (>5 × ULN)||3%||5%|
|Creatine Kinase (≥10 × ULN)||3%||3%|
|Serum Amylase (>2.0 × ULN)||3%||2%|
Amylase and Lipase Elevations and Pancreatitis
In Studies 108 and 110, seven subjects treated with Vidara with elevated amylase levels had associated symptoms, such as nausea, low back pain, abdominal tenderness, biliary pancreatitis and pancreatitis. Of these seven, two subjects discontinued Vidara due to elevated amylase and/or lipase; one subject experienced recurrence of adverse events when Vidara was restarted. No subject treated with Vidara disoproxil fumarate had associated symptoms or discontinued treatment.
Changes from baseline in total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, and total cholesterol to HDL ratio among subjects treated with Vidara and Vidara disoproxil fumarate are presented in Table 3.
|Vidara Disoproxil Fumarate |
|Baseline||Week 48||Baseline||Week 48|
|Total Cholesterol (fasted)||188 [n=835]||0 [n=772]||193 [n=423]||-25 [n=394]|
|HDL-Cholesterol (fasted)||60 [n=835]||-4 [n=771]||61 [n=423]||-10 [n=394]|
|LDL-Cholesterol (fasted)||116 [n=835]||+6 [n=772]||120 [n=423]||-11 [n=394]|
|Triglycerides (fasted)||102 [n=836]||+11 [n=773]||102 [n=423]||-10 [n=394]|
|Total Cholesterol to HDL ratio||3 [n=835]||0 [n=771]||3 [n=423]||0 [n=394]|
Do not take Vidara together with adefovir (Hepsera), or with combination medicines that contain Vidara (Atripla, Complera, or Truvada).
Vidara should not be given to a child with HIV who is younger than 2 years old. Vidara should not be used to treat hepatitis B in anyone younger than 18 years old.
Some people develop lactic acidosis while taking Vidara. Early symptoms may get worse over time and this condition can be fatal. Get emergency medical help if you have even mild symptoms such as: muscle pain or weakness, numb or cold feeling in your arms and legs, trouble breathing, stomach pain, nausea with vomiting, fast or uneven heart rate, dizziness, or feeling very weak or tired.
Vidara can also cause severe or life-threatening effects on your liver. Call your doctor at once if you have any of these symptoms while taking Vidara: nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
If you have hepatitis B you may develop liver symptoms after you stop taking this medication, even months after stopping. Your doctor may want to check your liver function for several months after you stop using Vidara. Visit your doctor regularly.
HIV/AIDS is usually treated with a combination of drugs. Use all medications as directed by your doctor. Do not change your doses or medication schedule without your doctor's advice. Every person with HIV or AIDS should remain under the care of a doctor.
Active ingredient matches for Vidara:
Tenofovir in Argentina.
List of Vidara substitutes (brand and generic names)
|Sort by popularity|
|Unit description / dosage (Manufacturer)||Price, USD|
|Tolak (Colombia, United States)|
|Tolak cream .04 g/g (Hill Dermaceuticals, Inc. (US))|
|Valten 300mg Tablet (Wockhardt Ltd)||$ 0.76|
|VALTEN 300 MG TABLET|
|VALTEN 300 MG TABLET 1 strip / 30 tablets each (Wockhardt Ltd)||$ 22.68|
|Vemlidy (Belgium, Canada, Denmark, Estonia, Finland, Germany, Greece, Iceland, Ireland, Japan, Lithuania, Netherlands, Norway, Romania, Slovenia, Sweden, Switzerland, United Kingdom, United States)|
|Vemlidy 25mg (Austria, Luxembourg)|
|Viread (Argentina, Australia, Austria, Belgium, Canada, Chile, China, Croatia (Hrvatska), Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Luxembourg, Mexico, Netherlands, New Zealand, Norway, Poland, Romania, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Thailand, Turkey, United Kingdom, United States)|
|Tablet, Film-Coated; Oral; Tenofovir Disoproxil Fumarate 245 mg (Abbott)|
|Tablet; Oral; Tenofovir Disoproxil Fumarate 245 mg (Abbott)|
|Tablet; Oral; Tenofovir Disoproxil Fumarate 300 mg (Abbott)|
|Viread 300 mg x 1000's (Abbott)|
|30 tablet in 1 bottle, plastic (Abbott)|
|Viread 300 mg x 30's (Abbott)|
|Viread 300 mg x 1 Bottle 30 Tablet (Abbott)|
|VIREAD 300 MG TABLET 1 strip / 30 tablets each (Abbott)||$ 37.79|
|VIREAD tab 300 mg x 30's (Abbott)||$ 39.68|
|Viread FC tab 300 mg 30's (Abbott)|
|Viread tablet 300 mg (Abbott)|
|Viread tablet, coated 300 mg/1 (Abbott)|
|Viread tablet, coated 200 mg/1 (Abbott)|
|Viread tablet, coated 250 mg/1 (Abbott)|
|Viread powder 40 mg/g (Abbott)|
|Viread tablet, coated 150 mg/1 (Abbott)|
|Viread 300mg Tablet (Abbott)||$ 1.26|
|Viread 123mg (Austria, Germany)|
|Viread 163mg (Austria, Germany)|
|Viread 204mg (Austria, Germany)|
|Viread 245mg (Austria, Germany, Hungary, Luxembourg, Switzerland)|
|Viread 33mg/g (Austria, Germany)|
|Viread Paranova (Iceland)|
|Virkil 300 mg x 1 Blister x 10 Tablet|
|Virkil 300 mg x 3 Blister x 10 Tablet|
|Virofob (Iceland, Romania)|
|Virofob 245 mg (Hungary)|
|Zifam Tenovir (Myanmar)|
|Zifam Tenovir FC tab 300 mg 6 x 10's (Zifam India)|
ReviewsThe results of a survey conducted on ndrugs.com for Vidara are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Vidara. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported usefulNo survey data has been collected yet
Consumer reported price estimatesNo survey data has been collected yet
Consumer reported time for resultsNo survey data has been collected yet
Consumer reported ageNo survey data has been collected yet
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology